Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy
Open Access
- 20 December 2021
- Vol. 7 (1) , 100348
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI GradeJournal of Clinical Oncology, 2015
- Prostaglandin E2‐mediated immunosuppression and the role of albumin as its modulatorHepatology, 2015
- Tying up PGE2 with albumin to relieve immunosuppression in cirrhosisNature Medicine, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Hyperbilirubinemia: a risk factor for infection in the surgical intensive care unitThe American Journal of Surgery, 2008
- Therapeutic Applications of Bilirubin and Biliverdin in TransplantationAntioxidants & Redox Signaling, 2007
- Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR ClampCancer Research, 2005
- Bilirubin inhibits iNOS expression and NO production in response to endotoxin in ratsHepatology, 2004
- Structural insights into human serum albumin‐mediated prostaglandin catalysisProtein Science, 2002